文献速递其他结缔组织病

弥漫性皮肤型系统性硬化症停用托珠单抗后的临床恶化:日本单中心经验

Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该单中心研究纳入15例接受托珠单抗治疗的弥漫性皮肤型系统性硬化症患者,治疗12个月后mRSS从20.4±10.7降至12.3±8.5(P=0.003),FVC从84.3±13.7%升至88.5±16.4%(P=0.04)。7例减量者中1例(14%)皮肤增厚加重,3例停药者均出现皮肤增厚加重和/或新发心包炎、关节炎、间质性肺病或肺动脉高压;另1例因不良事件停药者出现多器官进展并死亡。作者认为长期使用托珠单抗可能获益,停药可致皮肤和内脏表现进展,减量而非停药是可行选择。

要点

  • 托珠单抗治疗12个月后mRSS从20.4±10.7降至12.3±8.5(P=0.003),FVC从84.3±13.7%升至88.5±16.4%(P=0.04)。
  • 7例减量者中1例(14%)皮肤增厚加重;3例停药者均出现皮肤增厚加重和/或新发心包炎、关节炎、间质性肺病或肺动脉高压。
  • 另1例因不良事件停药者出现皮肤、肺、下消化道和肾脏多器官进展并死亡。

核心结论

  • 作者认为长期使用托珠单抗可能对弥漫性皮肤型系统性硬化症患者有益。
  • 停用托珠单抗可导致皮肤和内脏表现进展。
  • 作者认为对获得显著临床改善的弥漫性皮肤型系统性硬化症患者,减量而非停药是可行选择。

研究设计与样本

  • 单中心队列数据库研究,纳入15例接受托珠单抗治疗的弥漫性皮肤型系统性硬化症患者。
  • 评估托珠单抗引入后改良Rodnan总皮肤厚度评分(mRSS)、预测用力肺活量(FVC)的系列变化及临床恶化事件。

主要发现

  • 托珠单抗治疗12个月后,mRSS从20.4±10.7降至12.3±8.5(P=0.003)。
  • 托珠单抗治疗12个月后,FVC从84.3±13.7%升至88.5±16.4%(P=0.04)。
  • 7例减量者中1例(14%)出现皮肤增厚加重。
  • 3例停药者均出现皮肤增厚加重和/或新发心包炎、关节炎、间质性肺病或肺动脉高压。
  • 另1例因不良事件停药者出现皮肤、肺、下消化道和肾脏多器官表现进展,导致死亡。

临床怎么用

  • 作者认为对获得显著临床改善的弥漫性皮肤型系统性硬化症患者,减量而非停药是可行选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate outcomes following the tapering or discontinuation of tocilizumab in patients with diffuse cutaneous SSc (dcSSc) in a real-world setting. METHODS: Fifteen patients who were treated with tocilizumab for dcSSc were selected from a single-centre cohort database and were evaluated for serial changes in the modified Rodnan total skin thickness score (mRSS) and predicted forced vital capacity (FVC) and the occurrence of clinical worsening events after the introduction of tocilizumab. RESULTS: Over 12 months of treatment with tocilizumab, the mRSS decreased from 20.4 ± 10.7 to 12.3 ± 8.5 (P = 0.003) and FVC increased from 84.3 ± 13.7% to 88.5 ± 16.4% (P = 0.04). Tocilizumab was tapered or discontinued in seven and three patients, respectively, after improvement in skin thickening without occurrence or progression of organ manifestations. One (14%) of seven patients who underwent tocilizumab tapering experienced a worsening of skin thickening, while all three patients who discontinued tocilizumab experienced a worsening of skin thickening and/or new development of pericarditis, arthritis, interstitial lung disease or pulmonary arterial hypertension. The additional patient who discontinued tocilizumab due to an adverse event experienced subsequent progression of multiple organ manifestations, including skin, lung, lower gastrointestinal and renal involvement, leading to mortality. CONCLUSION: Our findings suggest potential benefits of prolonged tocilizumab use in dcSSc patients. The discontinuation of tocilizumab can lead to the progression of skin and visceral manifestations. Tapering rather than the discontinuation of tocilizumab is a viable option in dcSSc patients who experience remarkable clinical improvement.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Isomura Y, Shirai Y, Kuwana M, et al. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology (Oxford). 2022. PMID: 35258561. doi:10.1093/rheumatology/keac136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。